Ghisallo Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Ghisallo Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3M	Buy	+1,200,000	New	+$16.8M	0.4%	47
2023 Q3	–	Sell	-125,000	Closed	-$5.1M	–	151
2023 Q2	$5.1M	Hold	125,000	–	–	0.61%	42
2023 Q1	$4.66M	Sell	125,000 -125,000	-50%	-$4.9M	1.12%	22
2022 Q4	$8.72M	Buy	+250,000	New	+$11.9M	1.55%	15
2021 Q4	–	Sell	-20,000	Closed	-$2.68M	–	501
2021 Q3	$2.68M	Sell	20,000 -15,000	-43%	-$2.27M	0.1%	241
2021 Q2	$5.67M	Buy	+35,000	New	+$2.73M	0.22%	118

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Ghisallo Capital Management's NTLA Position: Q2 2026 in Review

Ghisallo Capital Management opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 1,200,000 shares worth $20.3M. The stake represents 0.4% of the portfolio and ranks #47 among its holdings. This is a return to the name: Ghisallo Capital Management previously reported a position in NTLA as recently as Q2 2023.

Ghisallo Capital Management first reported a position in NTLA in Q2 2021 and has held it in 6 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Ghisallo Capital Management held 1,200,000 shares of Intellia Therapeutics worth $20.3M as of Q2 2026.
Intellia Therapeutics was a new Ghisallo Capital Management position in Q2 2026.
Intellia Therapeutics made up 0.4% of Ghisallo Capital Management's portfolio in Q2 2026, its #47 holding.
Ghisallo Capital Management first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 6 quarters since.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.